US2013309268A1PendingUtilityA1

Compositions including transfer factor derived from eggs

50
Individually held — no corporate assignee on recordPriority: Sep 21, 2000Filed: Feb 22, 2002Published: Nov 21, 2013
Est. expirySep 21, 2020(expired)· nominal 20-yr term from priority
Inventors:William J. HennenDavid Lisonbee
A61K 39/292A61P 37/02C07K 14/52A61K 39/165A61K 38/00C07K 14/465A61K 39/245A61K 39/00A61P 31/12
50
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

A non-mammalian transfer factor, compositions including the non-mammalian transfer factor, and methods for generating and preparing the non-mammalian transfer factor. The non-mammalian transfer factor may have specificity for one or more antigens. A method of using the non-mammalian transfer factor includes administering either antigen-specific non-mammalian transfer factor or antigen non-specific non-mammalian transfer factor to mammals to treat or prevent pathogenic infections in the mammals.

Claims

exact text as granted — not AI-modified
1 . An orally administrable composition for eliciting a T cell-mediated immune response by a treated animal, comprising an extract of an egg of a non-mammalian source animal, said extract in a state for administration to the treated animal and including at least one type of non-mammalian transfer factor specific for an antigen of at least one of rubeola virus, mumps virus, rubella virus, Epstein-Ban virus and hepatitis B virus, for transferring cellular immunity to the treated animal in vivo, present in a concentration greater than said non-mammalian transfer factor was present in said egg, and being generated by way of a T cell-mediated immune response of said non-mammalian source animal to at least one antigenic agent. 
     
     
         2 . The orally administrable composition of  claim 1 , wherein said at least one type of non-mammalian transfer factor includes transfer factor molecules having molecular weights of about 4,000 Da to about 5,000 Da. 
     
     
         3 . The orally administrable composition of  claim 1 , wherein said non-mammalian transfer factor comprises avian transfer factor. 
     
     
         4 . The orally administrable composition of  claim 3 , wherein said avian transfer factor comprises chicken transfer factor. 
     
     
         5 . The orally administrable composition of  claim 1 , wherein said non-mammalian transfer factor comprises at least one of amphibian transfer factor, reptilian transfer factor, and fish transfer factor. 
     
     
         6 . (canceled) 
     
     
         7 . (canceled) 
     
     
         8 . The orally administrable composition of  claim 1 , wherein said at least one type of non-mammalian transfer factor transfers to the treated animal, in vivo, cellular immunity against at least a pathogen exhibiting said at least one antigenic agent. 
     
     
         9 . The orally administrable composition of  claim 1 , wherein said at least one type of non-mammalian transfer factor causes the treated animal to initiate a T cell-mediated immune response to at least one pathogen within about 48 hours of administration of the composition to the treated animal. 
     
     
         10 . The orally administrable composition of  claim 9 , wherein said at least one type of non-mammalian transfer factor causes the treated animal to initiate a T cell-mediated immune response to at least a pathogen exhibiting said at least one antigenic agent within about 48 hours of administration of the composition to the treated animal. 
     
     
         11 . The orally administrable composition of  claim 1 , wherein the treated animal comprises a mammal. 
     
     
         12 . An orally administrable composition, comprising:
 a carrier; and   an egg extract from an egg of a non-mammalian source animal, said egg extract including:
 non-mammalian transfer factor for transferring cellular immunity against a specific antigenic agent of a vaccine to a treated mammal in vivo, said non-mammalian source animal having borne the egg from which said egg extract was obtained, a concentration of said non-mammalian transfer factor in the composition being greater than a concentration of said non-mammalian transfer factor in the egg. 
   
     
     
         13 . The orally administrable composition of  claim 12 , wherein said non-mammalian transfer factor causes said treated animal to elicit a T cell immune response. 
     
     
         14 . The orally administrable composition of  claim 12 , wherein said non-mammalian transfer factor transfers to said treated mammal cellular immunity against a mammalian pathogen exhibiting said at least one antigenic agent. 
     
     
         15 . The orally administrable composition of  claim 12 , wherein said non-mammalian transfer factor transfers to said treated mammal cellular immunity against at least one of rubeola virus, mumps virus, rubella virus, hepatitis B virus, and  H. pylori.    
     
     
         16 . The orally administrable composition of  claim 12 , wherein said mammalian-specific pathogen against which said non-mammalian transfer factor is generated comprises at least one antigen of at least one of rubeola virus, mumps virus, rubella virus, Epstein-Ban Virus, hepatitis B virus, and  H. pylori.    
     
     
         17 . The orally administrable composition of  claim 12 , wherein said non-mammalian transfer factor comprises avian transfer factor. 
     
     
         18 . The orally administrable composition of  claim 17 , wherein said non-mammalian transfer factor comprises chicken transfer factor. 
     
     
         19 . The orally administrable composition of  claim 12 , wherein said non-mammalian transfer factor comprises non-avian transfer factor. 
     
     
         20 . The orally administrable composition of  claim 12 , wherein said egg extract includes transfer factor molecules having molecular weights of about 4,000 Da to about 5,000 Da. 
     
     
         21 . The orally administrable composition of  claim 12 , wherein said carrier is configured for application to skin of the treated mammal. 
     
     
         22 . The orally administrable composition of  claim 12 , wherein said carrier is configured for oral administration to the treated mammal. 
     
     
         23 . The orally administrable composition of  claim 12 , wherein said carrier is configured for nasal administration to the treated mammal. 
     
     
         24 . The orally administrable composition of  claim 12 , wherein said carrier is configured for parenteral administration to the treated mammal.

Join the waitlist — get patent alerts

Track US2013309268A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.